Literature DB >> 11125881

Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase.

M M Lederman1, R McKinnis, D Kelleher, A Cutrell, J Mellors, M Neisler, E Cooney, D W Haas, R Haubrich, J Stanford, J Horton, A Landay, W Spreen.   

Abstract

OBJECTIVE: To characterize early and later indices of cellular restoration among HIV-1 infected persons treated with abacavir and one protease inhibitor and to identify predictors of CD4 cell increases.
METHODS: Flow-cytometric analyses of lymphocyte phenotypes among 71 antiretroviral treatment naive adults in a 48 week treatment trial.
RESULTS: During the first 4 weeks of therapy, increases in naive and memory CD4 cells and in B cells were seen; naive CD8 cells increased while CD8 cells remained stable as memory CD8 cells decreased. During the second phase total CD4 and naive CD4 and CD8 cells increased while total CD8 and memory CD8 cells decreased. The numbers of CD4 cells that expressed CD28 increased from a median of 308 x 10(6)/l at baseline to 477 x 10(6)/l at week 48. Higher baseline plasma HIV-1 RNA levels predicted the magnitude of early CD4 (r = 0.35; P = 0.01), memory CD4 (r = 0.38; P = 0.001) and CD28 CD4 cell (r = 0.29; P = 0.01) restoration but was not related to second phase changes. Younger age predicted a greater second phase (but not first phase) increase in naive CD4 cells (r = -0.31; P = 0.03).
CONCLUSIONS: Higher baseline levels of HIV-1 replication determine the magnitude of first phase CD4 cell increases after suppression of HIV-1 replication. Second phase (primarily naive) CD4 cell increases are not related to HIV-1 replication but are inversely relate to age suggesting that thymic potential is a major determinant of long term cellular restoration in HIV-1 infected persons receiving antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11125881     DOI: 10.1097/00002030-200012010-00002

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  22 in total

1.  Decreases in IL-7 levels during antiretroviral treatment of HIV infection suggest a primary mechanism of receptor-mediated clearance.

Authors:  Jessica N Hodge; Sharat Srinivasula; Zonghui Hu; Sarah W Read; Brian O Porter; Insook Kim; Joann M Mican; Chang Paik; Paula Degrange; Michele Di Mascio; Irini Sereti
Journal:  Blood       Date:  2011-07-21       Impact factor: 22.113

2.  Asymptomatic CMV Replication During Early Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower CD4/CD8 Ratio During HIV Treatment.

Authors:  Davey M Smith; Masato Nakazawa; Michael L Freeman; Christy M Anderson; Michelli F Oliveira; Susan J Little; Sara Gianella
Journal:  Clin Infect Dis       Date:  2016-09-06       Impact factor: 9.079

3.  Baseline immune phenotypes and CD4+ T lymphocyte responses to antiretroviral therapy in younger versus older HIV-infected individuals.

Authors:  Risa M Hoffman; Beth D Jamieson; Ronald J Bosch; Judith Currier; Christina M R Kitchen; Ingrid Schmid; Yuda Zhu; Kara Bennett; Ronald Mitsuyasu
Journal:  J Clin Immunol       Date:  2011-06-04       Impact factor: 8.317

4.  Body mass index and CD4+ T-lymphocyte recovery in HIV-infected men with viral suppression on antiretroviral therapy.

Authors:  Brandon Palermo; Ronald J Bosch; Kara Bennett; Jeffrey M Jacobson
Journal:  HIV Clin Trials       Date:  2011 Jul-Aug

5.  Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067.

Authors:  Ronald D'Amico; Yijun Yang; Donna Mildvan; Scott R Evans; Carol T Schnizlein-Bick; Richard Hafner; Nancy Webb; Michael Basar; Robert Zackin; Mark A Jacobson
Journal:  J Clin Immunol       Date:  2005-03       Impact factor: 8.317

Review 6.  Cognitive impairment in older HIV-1-seropositive individuals: prevalence and potential mechanisms.

Authors:  Victor G Valcour; Cecilia M Shikuma; Michael R Watters; Ned C Sacktor
Journal:  AIDS       Date:  2004-01-01       Impact factor: 4.177

7.  Impact of age on markers of HIV-1 disease.

Authors:  Vanessa Pirrone; David J Libon; Christian Sell; Chad A Lerner; Michael R Nonnemacher; Brian Wigdahl
Journal:  Future Virol       Date:  2013-01       Impact factor: 1.831

8.  Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions.

Authors:  Rita B Effros; Courtney V Fletcher; Kelly Gebo; Jeffrey B Halter; William R Hazzard; Frances McFarland Horne; Robin E Huebner; Edward N Janoff; Amy C Justice; Daniel Kuritzkes; Susan G Nayfield; Susan F Plaeger; Kenneth E Schmader; John R Ashworth; Christine Campanelli; Charles P Clayton; Beth Rada; Nancy F Woolard; Kevin P High
Journal:  Clin Infect Dis       Date:  2008-08-15       Impact factor: 9.079

9.  The influence of race and comorbidity on the timely initiation of antiretroviral therapy among older persons living with HIV/AIDS.

Authors:  Winston E Abara; Lerissa Smith; Shun Zhang; Amanda J Fairchild; Harry J Heiman; George Rust
Journal:  Am J Public Health       Date:  2014-09-11       Impact factor: 9.308

10.  Combination antiretroviral therapy with raltegravir leads to rapid immunologic reconstitution in treatment-naive patients with chronic HIV infection.

Authors:  Suresh Pallikkuth; Margaret A Fischl; Savita Pahwa
Journal:  J Infect Dis       Date:  2013-08-06       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.